SCHEMBL6774534

SCHEMBL6774534

CC1(C)SCCN(S(=O)(=O)c2ccc(-c3ccc(CNc4ccc(Cl)c(C(F)(F)F)c4)cc3)cc2)[C@H]1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 11/20 0.46
MMP2 P08253 7/20 0.46
ADAM17 P78536 6/20 0.46
MMP1 P03956 11/20 0.44
MMP3 P08254 6/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
MMP7 P09237 5/20 0.42
MMP9 P14780 4/20 0.42
MMP14 P50281 1/20 0.42
MMP8 P22894 2/20 0.42
MAPT P10636 4/20 0.41
USP2 O75604 2/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6774541 1.00 MMP13 (0.46) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6768858 0.90 MMP13 (0.49) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6768852 0.90 MMP13 (0.49) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6768859 0.81 MMP13 (0.47) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6768854 0.81 MMP13 (0.47) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6769235 0.81 MMP13 (0.62) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6769232 0.81 MMP13 (0.62) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6770700 0.80 MMP1 (0.57) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6770703 0.80 MMP1 (0.57) MMP13MMP2ADAM17MMP1MMP3
SCHEMBL6765886 0.80 MMP13 (0.46) MMP13MMP2ADAM17MMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686355-B2 TREATING HEART DISEASE, MULTIPLE SCLEROSIS, ARTHRITIS, ATHEROSCLEROSIS, AND OSTEOPOROSIS; ANTICANCER AGENTS WARNER-LAMBERT COMPANY 2004-02-03 US disclosed
US-20020156074-A1 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors BARVIAN NICOLE CHANTEL (US) 2002-10-24 US disclosed
EP-1233016-A1 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2002-08-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156074-A1 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors MMP3, MMP9, MMP13 MMP13 3/4885MMP2 7/4885ADAM17 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.